An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Risperidone, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Positron Emission Tomography (PET)
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with schizophrenia according to the diagnostic criteria of DSM-IV taking not more than one oral antipsychotic medication within 28 days of study entry a score below 120 at pre-treatment on the Positive and Negative Syndrome Scale Score (PANSS), a scale for the measurement of symptoms of schizophrenia Exclusion Criteria: Diagnosis of psychiatric disease other than schizophrenia according to the diagnostic criteria of DSM-IV history of Parkinson's disease, seizure disorder, cerebrovascular accident, diabetes mellitus, clinically significant gastrointestinal disorders, or severe impairment of the liver or kidneys drug allergy or hypersensitivity to antipsychotics